Portfolio

Journalism dedicated to psychedelics, consciousness technologies and the future of wellness.

Luminous Mind is dedicated to develop superior and differentiated treatments for Central Nervous System (CNS) disorders, including depression, PTSD, pain, anxiety, and addiction. They apply a rigorous therapeutic discovery and development process that includes the repurposing of existing, abandoned, and developmental compounds for new indications.

Mauhn is a human-level AI company with a focus on ethics and safety, and a unique approach to make neural networks reason both through induction and deduction.

MAPS is a non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana. The organization is focused on developing psychedelics and marijuana into prescription medicines, training therapists and working to establish a network of treatment centers, supporting scientific research into spirituality, creativity, and neuroscience, and educating the public honestly about the risks and benefits of psychedelics and marijuana.

Mindstate Design Labs is a preclinical-stage biotechnology company developing the next generation of psychedelic-inspired therapeutics for intractable mental health conditions. The company maps the biological basis of the varieties of psychedelic experiences and uses that map to design therapeutic states of mind to be applied in medically supervised settings to heal the root causes of mental health disorders.

Meeko has embraced a new era of mental health care by creating a platform with which employees can offer psychedelic-assisted therapy offerings via employee benefits.

Momentu is a corporate mental health platform intended to address the mental health challenges of employees. The company offers emotional tests for workers to understand their needs and provides personalized support through digital content, therapy, and coaching sessions, enabling companies to reduce work absenteeism in employees and increase the work productivity of their teams.

Nuanced detects AI-generated images to protect the integrity and authenticity of services.

Outro is the world’s first comprehensive, personalized, and science-based platform to help people safely reduce or stop antidepressants that are no longer needed. Outro combines a user-friendly digital app with a specialized care team to deliver a safe and convenient path off antidepressants.

Pelago, formerly Quit Genius, is the world’s leading digital clinic for substance use management. With the realization that people who suffer from substance use feel isolated and alone, they partnered to create an optimistic new brand that addresses the stigma around addiction and makes substance use support approachable and accessible.

Progressive Therapeutics develop novel therapeutics designed for the treatment of mental health. They offer innovative solutions for various mental health needs of women, helping patients to cure their mental health issues to lead a healthy lifestyle.

Psylo is a drug development company that focuses on next-generation psychedelics. With psychedelic molecules as the starting point, their goal is to develop medicines that are widely available as improved treatments to currently available SSRI medications.